Cargando…

An overview of abuse-deterrent opioids and recommendations for practical patient care

Despite advances in the treatment of severe intractable pain, opioids remain a critical and appropriate component of treatment. However, abuse, misuse, and diversion of prescription opioids are significant public health concerns. Opioid abuse-deterrent formulations (ADFs) are one component of an opi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adler, Jeremy A, Mallick-Searle, Theresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045950/ https://www.ncbi.nlm.nih.gov/pubmed/30026658 http://dx.doi.org/10.2147/JMDH.S166915

Ejemplares similares

Mitigation of IV Abuse Through the Use of Abuse‐Deterrent Opioid Formulations: An Overview of Current Technologies
por: Rauck, Richard L.
Publicado: (2019)

Dancing with Deterrents: Understanding the Role of Abuse‐Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain
por: Mitchell, Megan T.
Publicado: (2019)

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
por: Coplan, PM, et al.
Publicado: (2016)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology
por: Dasgupta, Nabarun, et al.
Publicado: (2021)

Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidance
por: Zhao, Liang, et al.
Publicado: (2021)

Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program
por: L. Keast, Shellie, et al.
Publicado: (2016)

How did you know you got the right pill? Prescription opioid identification and measurement error in the abuse deterrent formulation era
por: Green, Traci C, et al.
Publicado: (2015)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

An overview of available drugs for management of opioid abuse during pregnancy
por: Laslo, Jillian, et al.
Publicado: (2017)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

Can abuse deterrent formulations make a difference? Expectation and speculation
por: Budman, Simon H, et al.
Publicado: (2009)

Oxycodone DETERx(®): A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain
por: Gudin, Jeff
Publicado: (2016)

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
por: Janoff, Shannon L., et al.
Publicado: (2016)

Dexmedetomidine Infusion to Facilitate Opioid Detoxification and Withdrawal in a Patient with Chronic Opioid Abuse
por: Upadhyay, Surjya Prasad, et al.
Publicado: (2011)

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations
por: Kibbe, AH, et al.
Publicado: (2018)

Determining Abuse Deterrence Performance of Poly (ethylene oxide) Using a Factorial Design
por: Joshi, Yogesh, et al.
Publicado: (2018)

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2015)

Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine
por: Rossiter, Louis F, et al.
Publicado: (2020)

Designing Opioids That Deter Abuse
por: Raffa, Robert B., et al.
Publicado: (2012)

Bed bug deterrence
por: Haynes, Kenneth F, et al.
Publicado: (2010)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2017)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users
por: Smith, Michael D., et al.
Publicado: (2017)

Deterrents and reinforcement : the psychology of insufficient reward /
por: Lawrence, Douglas H.
Publicado: (1962)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects
por: Webster, Lynn R., et al.
Publicado: (2018)

Hepatitis Infection in the Treatment of Opioid Dependence and Abuse
por: Kresina, Thomas F, et al.
Publicado: (2008)

Prescription opioid abuse: pharmacists’ perspective and response
por: Cochran, Gerald, et al.
Publicado: (2016)

Epigenetic Modulation of Opioid Receptors by Drugs of Abuse
por: Reid, Ke Zhang, et al.
Publicado: (2022)

Economic Burden of Prescription Opioid Misuse and Abuse
por: Strassels, Scott
Publicado: (2009)

The Value of Vengeance and the Demand for Deterrence
por: Crockett, Molly J., et al.
Publicado: (2014)

DEET as a feeding deterrent
por: Lu, WeiYu, et al.
Publicado: (2017)

Fraud in publications-retractions and deterrents
por: Bhaskar, S Bala
Publicado: (2019)

Deterrence Rediscovered: NATO and Russia
por: Rynning, Sten
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7mtq17ulfhpkojb39qklbtjr5r